{"id":"NCT01890759","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation","officialTitle":"Immunogenicity and Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Subjects Aged 9 to 23 Months in India and in the Russian Federation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06-25","primaryCompletion":"2016-04-12","completion":"2016-04-12","firstPosted":"2013-07-02","resultsPosted":"2017-08-21","lastUpdate":"2022-04-19"},"enrollment":300,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Meningitis","Meningococcal Infection"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal Diphtheria Toxoid Vaccine","otherNames":["Menactra®"]}],"arms":[{"label":"Meningococcal Diphtheria Toxoid Vaccine","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the immunogenicity and safety of Menactra® vaccine given as a two-dose series in infants and toddlers.\n\nPrimary Objectives:\n\n* To assess the seroprotection rate (percentage of subjects with a serum bactericidal assay using human complement \\[SBA-HC\\] titer ≥ 1:8) 28 days after the second of 2 doses of Menactra® administered 3 to 6 months apart.\n\nSecondary Objectives:\n\n* To assess the immune responses to meningococcal antigens (serogroups A, C, Y, and W-135) 28 days following the second vaccination with Menactra® using SBA-HC and SBA-BR titers.\n* To assess the safety profile of Menactra® after each and any vaccination.","primaryOutcome":{"measure":"Percentage of Participants Achieving Seroprotection Using a Serum Bactericidal Assay Human Complement With Antibody Titers ≥ 1:8 for Meningococcal Serogroups A, C, Y, and W-135 Before and Following Vaccination With Menactra®","timeFrame":"Day 0 (pre-vaccination) and Day 28 post-second vaccination","effectByArm":[{"arm":"Russian Federation","deltaMin":45.5,"sd":null},{"arm":"India","deltaMin":55,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":20},"locations":{"siteCount":8,"countries":["India","Russia"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":100},"commonTop":["Injection site Tenderness","Irritability","Appetite lost","Crying abnormal","Injection site Erythema"]}}